Non-Invasive PGT (niPGT): Emerging Alternative to Embryo Biopsy

Preimplantation genetic testing for aneuploidy (PGT-A) has been standard practice for over a decade — a few cells are biopsied from each blastocyst and tested for chromosomal abnormalities. The biopsy is technically routine at experienced labs, but it's not zero-risk: some embryos are damaged, and the sampling is limited to a small portion of the embryo.

Non-invasive PGT-A (niPGT-A) is the emerging alternative: instead of biopsying the embryo, DNA released into the culture medium during blastocyst development is analyzed. No embryo cells removed. No biopsy risk. This piece walks through how the technology works, what the current evidence supports, and where niPGT-A stands in 2026 versus standard PGT-A.

How niPGT-A Works

Developing embryos naturally shed small amounts of DNA into the surrounding culture medium as cells divide and some die off. niPGT-A analyzes this "spent" medium after blastocyst culture:

1. Embryos are cultured in a modified protocol that preserves the culture medium.
2. Media are collected from each embryo at the blastocyst stage.
3. The cell-free DNA in the medium is extracted, amplified, and analyzed using next-generation sequencing.
4. Chromosomal results are reported for each embryo — without any embryo cells having been removed.

The result is comparable in format to a standard PGT-A report: euploid (normal), aneuploid (abnormal chromosomes), or mosaic (mixed cell populations).

The Advantage: No Biopsy Trauma

The main appeal of niPGT-A is what it doesn't do:

• No physical intervention on the embryo itself
• No embryologist skill dependency for biopsy quality (though media collection technique still matters)
• No possibility of biopsy-related embryo damage (small but real risk with trophectoderm biopsy)
• No requirement for the embryo to reach a specific developmental stage suitable for biopsy

For patients who have concerns about biopsy risk — particularly those with previously biopsied embryos that failed to implant — the non-invasive framing is meaningful.

The Evidence: A Moving Target

The Concordance Question

The most important technical question about niPGT-A is: how often does it agree with standard PGT-A on the same embryos? Studies published between 2023 and 2026 have shown wide variability — concordance rates from below 60% in early studies to above 85% in later work with refined technique.

The discrepancies are worth understanding:

• Maternal DNA contamination can affect niPGT-A results. Culture media can contain trace maternal DNA from cumulus cells or granulosa cells that weren't fully removed during embryo preparation. This has largely been addressed by protocol refinements but remains a consideration.
• DNA release variability means some embryos release more analyzable DNA than others. Low-DNA samples produce less reliable results.
• Mosaic embryos may be represented differently in media DNA than in trophectoderm biopsies — potentially better, potentially worse.

Ongoing research is refining protocols and improving reliability. As of 2026, niPGT-A is best understood as a useful emerging technique that hasn't fully replaced standard PGT-A.

Colombia Availability

niPGT-A is available at select Colombian IVF programs, generally those associated with genetics research programs or major academic hospitals. Availability varies significantly by clinic. If you're specifically interested in niPGT-A over standard PGT-A, this needs to be verified at consultation — not all programs offer it.

Pricing typically runs similar to standard PGT-A per embryo (both are $400–$800 per embryo in typical Colombian pricing). Some programs offer both together, some only one, some offer patients a choice.

What This Means for Your Cycle Decision

Standard PGT-A is still the default

For most patients, standard trophectoderm biopsy PGT-A remains the recommended approach when chromosomal screening is indicated. The evidence base is more mature, and outcomes data is more established.

niPGT-A worth considering when:

• You have philosophical or practical concerns about embryo biopsy
• You have very few embryos and want to minimize any intervention risk
• Your clinic offers it with clear communication about its emerging status
• You've had prior biopsy-related concerns (though this is uncommon)

Combined approach in some cases:

Some programs offer combined analysis — niPGT-A on all embryos initially, followed by standard biopsy PGT-A on the top candidates for confirmation. This is more expensive but produces higher-confidence results.

What niPGT-A Doesn't Change

Regardless of which testing method is used, the scope of Colombian IVF genetic testing remains the same: chromosomal screening (aneuploidy, in PGT-A / niPGT-A) and testing for specific known genetic diseases (PGT-M). Sex selection or family balancing for non-medical reasons is not part of responsible Colombian IVF practice. This is a consistent framework across genetic testing methods.

Colombia's #1 Western Hemisphere / #22 global WHO healthcare ranking (per the 2000 World Health Report) reflects the underlying quality of the medical infrastructure. Individual clinic and physician credentialing (SCCP membership for related specialties, ReTHUS registration for physicians) matters for genetic testing quality regardless of methodology.